CFDE Data Portal | Search LOC105372705

	Label	Description
	LOC105372705 Gene (Entity type)	ENSG00000283078 - uncharacterized LOC105372705
	GSE195663 cisplatin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 7 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE182680 GSE182683 dexamethasone 10 v 13 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE229973 cisplatin 3 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE115550 BRD4 inhibition 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE203329 HCC knockout 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE128255 NDP knockdown stem cell 3 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE168401 harmine U2OS 1 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE130401 trametinib YAP 4 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS

LOC105372705

ENSG00000283078 - uncharacterized LOC105372705

GSE195663 cisplatin 0 v 1 human up

A Gene Set from LINCS

GSE195663 cisplatin 7 v 1 human up

A Gene Set from LINCS

GSE182680 GSE182683 dexamethasone 10 v 13 human up

A Gene Set from LINCS

GSE229973 cisplatin 3 v 7 human up

A Gene Set from LINCS

GSE115550 BRD4 inhibition 2 v 1 human up

A Gene Set from LINCS

GSE203329 HCC knockout 2 v 1 human up

A Gene Set from LINCS

GSE128255 NDP knockdown stem cell 3 v 0 human up

A Gene Set from LINCS

GSE168401 harmine U2OS 1 v 3 human up

A Gene Set from LINCS

GSE130401 trametinib YAP 4 v 3 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.